The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2017 | Clinical factors in the selection of patients for first-line immunotherapy of lung cancer
Benjamin Besse, MD, PhD, Institut Gustave Roussy, Paris, France, discusses clinical factors in the selection of non-small cell lung cancer (NSCLC) patients for first-line immunotherapy.
In particular, Prof Besse discusses the anticipated approval of the immune checkpoint inhibitor, pembrolizumab (Keytruda®) in the treatment of stage IV NSCLC patients who have not received any previous therapy. A key question is to identify which patients are most likely to benefit from treatment with pembrolizumab.
Patients with tumours expressing high levels of PD-L1 are eligible for pembrolizumab therapy. However, other factors need to be considered, such as the absence of other genetic abnormalities, a good performance status and stable brain metastases.
Prof Besse highlights that tobacco consumption is probably the most appropriate clinical factor in patient selection as never-smokers hardly benefit from immunotherapy.
Recorded at the 2017 meeting of the British Thoracic Oncology Group (BTOG) in Dublin, Ireland.
